Assessment of efficacy and safety of various adjuvant formulations with a total soluble extract of Trichinella spiralis.
Trichinellosis, a re-emerging zoonosis in several countries and pig, is the main species responsible for its transmission to human. Vaccination of swine could be an alternative to prevent the risk of human contamination. In order to develop an efficient and safe inactivate vaccine, the choice of the adjuvant is an important issue. The aim of this study was to develop and select potent and safe adjuvants by screening them in an experimental model with a crude soluble antigen from L1 muscular larvae (ML) of Trichinella spiralis (Ts). The efficacy was checked by the quantification of specific antibody levels. Specific and non-specific IgE antibody levels were also assessed. Safety was checked by the assessment of the local reaction at the injection site. Various Montanide ISA adjuvant formulations including water in oil, oil in water and multiphasic emulsions, but also nanoparticles or microbeads were tested. The results clearly showed differences between the antibody responses induced by the adjuvants and demonstrated the necessity to use an adjuvant to obtain a specific IgG (IgG1 or IgG2a) response directed against the total soluble extract of Ts. All the formulations enhanced the humoral immune response. The origin of the oil contained in the emulsions played an important role on the efficacy. Indeed emulsions based on mineral oils were more efficient than those based on metabolisable oils. However it was linked with stronger local reactions. Multiphasic and oil in water emulsions but also nanoparticles failed to induce IgG2a antibody levels. Microbeads and water in oil formulations based on mineral oils were more efficient. This experimentation allowed then the selection of several adjuvants which efficacy will be further investigated by a challenge test and an analysis of the cellular populations involved in the mechanism of the immune response.
Aucouturier
J
J
SEPPIC, 75, Quai d'Orsay, 75321 Paris, France. jerome.aucouturier@airlique.com
Deville
S
S
Perret
C
C
Vallée
I
I
Boireau
P
P
D000276:Adjuvants, Immunologic; D000818:Animals; D005260:Female; D006801:Humans; D008353:Mannitol / Q000031:analogs & derivatives; D051379:Mice; D008815:Mice, Inbred Strains; D009829:Oleic Acids; D012449:Safety; D017160:Trichinella spiralis / Q000276:immunology*; D014235:Trichinellosis / Q000276:immunology* / Q000517:prevention & control; D015164:Vaccines, Inactivated
D000276:Adjuvants, Immunologic; D009829:Oleic Acids; D015164:Vaccines, Inactivated; C001681:mannide monooleate; D008353:Mannitol